In its initial trial the Tolerx drug caused a mononucleosis-like syndrome soon after treatment.

FORBES: Magazine Article

It could work like this: a drug would be provisionally approved for its effects on biomarkers or patients reactions.

FORBES: Big Pharma Failures Light the Way to Change

And a merger might force Bristol to give up its own promising Acomplia-like drug.

FORBES: Why Bristol And Sanofi Shouldn't Merge

The evolution into a branded drug firm is already forcing Barr to act very poodle-like with its old enemies.

FORBES: Lawyers In Lab Coats

Only giant clinical trials measuring hard outcomes like heart attacks, strokes and deaths can tell doctors whether a heart drug's benefits outweigh its risks.

FORBES: The Statin Showdown